Clinical trials: Severe Allergic Asthma
Moderate to Severe Allergic Asthma
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
The study was designed to collect data about inadequately controlled moderate to severe allergic asthma in subjects 6 to < 12 years of age, managed in a real-world setting.
- Trial name
- NCT01362621
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 474 people
- Sponsor
- Novartis Pharmaceuticals
Intrinsic Asthma, Allergic Asthma
The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children
The aim of investigator´s clinical trial is to investigate 52 patients aged three to five years with viral-induced asthma and 52 patients aged three to five years with allergic asthma.
- Conditions
- Intrinsic Asthma, Allergic Asthma, Allergy, Bronchial Hyperresponsiveness
- Trial name
- BHR (NCT01144910)
- Testing
- methacholine challenge test
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Type I-Allergy
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)
- Trial name
- NCT00666341
- Testing
- rPhleum
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Allergopharma GmbH & Co. KG
Asthma
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
The purpose of this trial is to compare the efficacy of 4 to 5 months of three treatments - omalizumab, corticosteroid therapy boost, and placebo - in reducing fall exacerbations in inner-city children and adolescents with…
- Trial name
- PROSE (NCT01430403)
- Testing
- Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS)
- Where
- 8 sites in United States
- Volunteers
- 478 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR)…
- Trial name
- NCT06151938
- Testing
- Standardised allergen extract from house dust mites
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ALK-Abelló A/S
Asthma
Dose Finding Study for QAW039 in Asthma
This study aims to demonstrate a clinically significant improvement in Forced Expiratory Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled by Inhaled Corticosteroid (ICS) therapy.
- Trial name
- NCT01437735
- Testing
- QAW039, Montelukast
- Where
- 206 sites in United States, Argentina and 20 more
- Volunteers
- 1,043 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Short Treatment with Omalizumab for Severe Asthma
The optimal duration of the treatment by OMA remains unclear when asthma is well controlled. Data suggest that a large part of patients with well controlled asthma can discontinue OMA therapy without any asthma control…
- Trial name
- SHORTEN (NCT04763447)
- Testing
- Attempt to withdrawal OMA treatment, Continuation of OMA treatment
- Where
- France
- Volunteers
- 234 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Disease
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.
- Trial name
- NCT00139152
- Testing
- Xolair
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Creighton University
Asthma
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.
- Trial name
- NCT00567476
- Testing
- Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA)
- Where
- Brazil
- Volunteers
- 116 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
- Trial name
- NCT00046748
- Testing
- Omalizumab
- Volunteers
- 484 people
- Sponsor
- Novartis Pharmaceuticals
Bronchial Asthma
An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma
This is a randomized, double-blind, comparative, parallel-group study of the efficacy and safety of Genolar® and Xolair® in the treatment of persistent atopic bronchial asthma of moderate and severe course, whose symptoms are…
- Trial name
- NAP (NCT04607629)
- Testing
- Genolar® + Symbicort®, Xolair® + Symbicort®
- Where
- 24 sites in Russia
- Volunteers
- 192 people
- Sponsor
- AO GENERIUM
Asthma
Laminar Airflow in Severe Asthma for Exacerbation Reduction
To ascertain whether home-based nocturnal TLA usage over a 12 month period can reduce exacerbations and improve asthma control and quality of life as compared to placebo, whilst being cost-effective and acceptable to adults with…
- Trial name
- LASER (NCT03058497)
- Testing
- Temperature-Controlled Laminar Airflow Device (Airsonett®)
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Portsmouth Hospitals NHS Trust
Allergic Asthma
Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy and safety of FB825 in adult patients with moderate-to-severe allergic asthma.
- Trial name
- NCT05008965
- Testing
- FB825
- Where
- 13 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Oneness Biotech Co., Ltd.
Asthma
Laminar Airflow in Severe Asthma for Exacerbation Reduction - 48 Month Follow-up.
Temperature-controlled Laminar Airflow (TLA) treatment delivered by the Airsonett treatment device is a new treatment for patients with allergic asthma.
- Trial name
- LASER-48 (NCT02813811)
- Where
- United Kingdom
- Volunteers
- 77 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Severe Allergic Asthma
Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma
Omalizumab is an anti-IgE recombinant humanized monoclonal antibody.The efficacy and tolerability of omalizumab have been demonstrated in patients with moderate-to-severe and allergic (IgE-mediated) asthma.
- Trial name
- OM-2009-XO (NCT01002976)
- Where
- Israel
- Sponsor
- Carmel Medical Center
Severe Asthma
3TR Asthma Biologics Cohort (ABC) Study
The 3TR-ABC study is a multicentre observational prospective cohort study platform that follows patients with severe asthma from the start of biological therapy and three years onwards.
- Trial name
- 3TR-ABC (NCT06126692)
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
House Dust Mite Allergy, House Dust Mite Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust…
- Trial name
- NCT06920771
- Testing
- PURETHAL Mites 50,000 AUeq/ml
- Where
- 68 sites in Bulgaria, Germany and 3 more
- Volunteers
- 691 people
- Sponsor
- HAL Allergy
Severe Asthma, Allergic Bronchopulmonary Aspergillosis (ABPA)
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
Asthma is severe when it cannot be controlled with maximum-dose inhaled therapies while management of comorbidities and other precipitating or aggravating factors has been optimized.
- Trial name
- MOSAIC (NCT05616338)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Montpellier
Allergic Asthma
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients
This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent…
- Trial name
- NCT07342803
- Testing
- LP-003 Injection, Omalizumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Longbio Pharma
Severe Asthma
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.
- Trial name
- PREDICTUMAB (NCT03476109)
- Testing
- Randomisation to omalizumab, Randomisation to mepolizumab
- Where
- 13 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain